Table 1 The peptides and antibodies used throughout this study. Note that all these peptides have a cysteine at their N terminus, which has been added for conjugating them to a carrier protein for the immunization.

MDR1 P1

C QDVSWFDDPK

799–808

#64840, #64841

MDR1 P3

C SEIDALEMSSNDSR

646–659

#65158, #64541

MDR1 P494

MPNTLEGNVTK

1027–1036

C494 (Commercial monoclonal antibody)

MXR P1

C VGTQFIR

178–184

#65158, #64541

MXR P2

C LAEIYVNSSFYK

332–343

#64795, #64850

MXR P3

C EISYTTSFCHQLR

366–378

#64795, #64850

MXR P4

C LFIHYISGYYR

454–465

#64853, #64851

MXR P5

C NDSTGIQNR

418–426

#64853, #64851

MRP1 P1

C PSDLLQQR

1511–1518

#A0151, #A0152

MRP1 P2

C DLWSLNK

240–246

#A0151, #A0152

NaK ATPase P1

C IPFNSTNK

478–485

#64845, #64846

NaK ATPase P2

C PTTPEWVK

74–81

#64845, #64846

NaK ATPase P3

C TGTLTQNR

368–375

#64855, #64856

NaK ATPase P4

C YEPAAVSE

11–07

#64855, #64856